The 2005 Database Explosion

By BIO-IT World

RESEARCH TOOLS · More than 700 'open' databases now available from around the world

BY KEVIN DAVIES

February 15, 2005 | The 2005 compendium of molecular biology databases compiled and published by Nucleic Acids Research shows a dramatic increase of 171 databases from 2004, bringing the new total up to 719.

The compendium, which is restricted to freely available life science databases that do not require downloading of special software (because of firewall restrictions), is accessible online at nar.oupjournals.org/ cgi/content/full/33/suppl_1/#TBL1.

Michael Galperin, an investigator at the National Center for Biotechnology Information at the NIH who coordinated the new compendium, says the compendium shows that "the open database movement is here to stay, and more and more people in the community (as well as in the financing bodies) now appreciate the importance of open databases in spreading knowledge."

This year's 12th annual database issue includes 719 databases, organized into 14 categories. The list includes new entries from countries such as Brazil, Cuba, Estonia, Greece, Hungary, and Malaysia.

Of the 548 databases featured in last year's compilation, 17 have been dropped from the list because they have been discontinued, merged into larger ones, or converted to commercial access. Galperin says that databases that offer valuable content "usually manage to survive, even if they have to change their funding scheme or migrate from one host institution to another."

The profusion of databases has little to do with personal credit, and certainly not financial remuneration. "Disk space is relatively cheap these days and database maintenance tools are fairly straightforward, so that a decent database can be created on a shoestring budget, often by a graduate student or as a result of a postdoctoral project," Galperin says.

While getting such projects off the ground is easy, maintaining and developing these resources with little or no funding requires "a commitment that can only be applauded" — particularly for scientists for whom English is not their native language.

The volume of immunology-related databases required the creation of a new category, largely in response to the genome project-fueled growth in data on immuno-polymorphisms, as well as a sprouting of plant-related genome databases.

Galperin's accompanying commentary is available at nar.oupjournals.org/cgi/ content/full/33/suppl_1/D5.* 








White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .